 | • レポートコード：MRC2312MG08346 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の速効型ヒトインスリン市場規模と予測を収録しています。・世界の速効型ヒトインスリン市場：売上、2018年-2023年、2024年-2029年 ・世界の速効型ヒトインスリン市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の速効型ヒトインスリン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「リスプロインスリン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 速効型ヒトインスリンのグローバル主要企業は、Sanofi、 Geropharm、 Wockhardt、 Novo Nordisk、 Eli Lilly and Company、 Mannkind、 Biocon、 Julphar、 ADOCIA、 Tonghua Dongbao Pharmaceutical、 Gan & Lee Pharmaceuticals、 Zhejiang Hisun Pharmaceutical、 Wuhan Biology Chemical Pharmacyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、速効型ヒトインスリンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の速効型ヒトインスリン市場：タイプ別、2018年-2023年、2024年-2029年 世界の速効型ヒトインスリン市場：タイプ別市場シェア、2022年 ・リスプロインスリン、アスパルトインスリン、グルリシンインスリン 世界の速効型ヒトインスリン市場：用途別、2018年-2023年、2024年-2029年 世界の速効型ヒトインスリン市場：用途別市場シェア、2022年 ・1型糖尿病、2型糖尿病 世界の速効型ヒトインスリン市場：地域・国別、2018年-2023年、2024年-2029年 世界の速効型ヒトインスリン市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における速効型ヒトインスリンのグローバル売上、2018年-2023年 ・主要企業における速効型ヒトインスリンのグローバル売上シェア、2022年 ・主要企業における速効型ヒトインスリンのグローバル販売量、2018年-2023年 ・主要企業における速効型ヒトインスリンのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Sanofi、 Geropharm、 Wockhardt、 Novo Nordisk、 Eli Lilly and Company、 Mannkind、 Biocon、 Julphar、 ADOCIA、 Tonghua Dongbao Pharmaceutical、 Gan & Lee Pharmaceuticals、 Zhejiang Hisun Pharmaceutical、 Wuhan Biology Chemical Pharmacy ************************************************************* ・調査・分析レポートの概要 速効型ヒトインスリン市場の定義 市場セグメント 世界の速効型ヒトインスリン市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の速効型ヒトインスリン市場規模 世界の速効型ヒトインスリン市場規模：2022年 VS 2029年 世界の速効型ヒトインスリン市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの速効型ヒトインスリンの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の速効型ヒトインスリン製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：リスプロインスリン、アスパルトインスリン、グルリシンインスリン 速効型ヒトインスリンのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：1型糖尿病、2型糖尿病 速効型ヒトインスリンの用途別グローバル売上・予測 ・地域別市場分析 地域別速効型ヒトインスリン市場規模 2022年と2029年 地域別速効型ヒトインスリン売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Sanofi、 Geropharm、 Wockhardt、 Novo Nordisk、 Eli Lilly and Company、 Mannkind、 Biocon、 Julphar、 ADOCIA、 Tonghua Dongbao Pharmaceutical、 Gan & Lee Pharmaceuticals、 Zhejiang Hisun Pharmaceutical、 Wuhan Biology Chemical Pharmacy ... |
This research report provides a comprehensive analysis of the Fast-acting Human Insulin market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Fast-acting Human Insulin market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Fast-acting Human Insulin, challenges faced by the industry, and potential opportunities for market players.
The global Fast-acting Human Insulin market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Fast-acting Human Insulin market presents opportunities for various stakeholders, including Type 1 Diabetes, Type 2 Diabetes. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Fast-acting Human Insulin market. Additionally, the growing consumer demand present avenues for market expansion.
The global Fast-acting Human Insulin market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Fast-acting Human Insulin market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Fast-acting Human Insulin market.
Market Overview: The report provides a comprehensive overview of the Fast-acting Human Insulin market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Lispro Insulin, Aspart Insulin), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Fast-acting Human Insulin market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Fast-acting Human Insulin market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Fast-acting Human Insulin market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Fast-acting Human Insulin market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Fast-acting Human Insulin market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Fast-acting Human Insulin market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Fast-acting Human Insulin, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Fast-acting Human Insulin market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Fast-acting Human Insulin market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Lispro Insulin
Aspart Insulin
Glulisine Insulin
Market segment by Application
Type 1 Diabetes
Type 2 Diabetes
Global Fast-acting Human Insulin Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Sanofi
Geropharm
Wockhardt
Novo Nordisk
Eli Lilly and Company
Mannkind
Biocon
Julphar
ADOCIA
Tonghua Dongbao Pharmaceutical
Gan & Lee Pharmaceuticals
Zhejiang Hisun Pharmaceutical
Wuhan Biology Chemical Pharmacy
Outline of Major Chapters:
Chapter 1: Introduces the definition of Fast-acting Human Insulin, market overview.
Chapter 2: Global Fast-acting Human Insulin market size in revenue and volume.
Chapter 3: Detailed analysis of Fast-acting Human Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Fast-acting Human Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Fast-acting Human Insulin capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Fast-acting Human Insulin Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Fast-acting Human Insulin Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Fast-acting Human Insulin Overall Market Size
2.1 Global Fast-acting Human Insulin Market Size: 2022 VS 2029
2.2 Global Fast-acting Human Insulin Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Fast-acting Human Insulin Sales: 2018-2029
3 Company Landscape
3.1 Top Fast-acting Human Insulin Players in Global Market
3.2 Top Global Fast-acting Human Insulin Companies Ranked by Revenue
3.3 Global Fast-acting Human Insulin Revenue by Companies
3.4 Global Fast-acting Human Insulin Sales by Companies
3.5 Global Fast-acting Human Insulin Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Fast-acting Human Insulin Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Fast-acting Human Insulin Product Type
3.8 Tier 1, Tier 2 and Tier 3 Fast-acting Human Insulin Players in Global Market
3.8.1 List of Global Tier 1 Fast-acting Human Insulin Companies
3.8.2 List of Global Tier 2 and Tier 3 Fast-acting Human Insulin Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Fast-acting Human Insulin Market Size Markets, 2022 & 2029
4.1.2 Lispro Insulin
4.1.3 Aspart Insulin
4.1.4 Glulisine Insulin
4.2 By Type – Global Fast-acting Human Insulin Revenue & Forecasts
4.2.1 By Type – Global Fast-acting Human Insulin Revenue, 2018-2023
4.2.2 By Type – Global Fast-acting Human Insulin Revenue, 2024-2029
4.2.3 By Type – Global Fast-acting Human Insulin Revenue Market Share, 2018-2029
4.3 By Type – Global Fast-acting Human Insulin Sales & Forecasts
4.3.1 By Type – Global Fast-acting Human Insulin Sales, 2018-2023
4.3.2 By Type – Global Fast-acting Human Insulin Sales, 2024-2029
4.3.3 By Type – Global Fast-acting Human Insulin Sales Market Share, 2018-2029
4.4 By Type – Global Fast-acting Human Insulin Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Fast-acting Human Insulin Market Size, 2022 & 2029
5.1.2 Type 1 Diabetes
5.1.3 Type 2 Diabetes
5.2 By Application – Global Fast-acting Human Insulin Revenue & Forecasts
5.2.1 By Application – Global Fast-acting Human Insulin Revenue, 2018-2023
5.2.2 By Application – Global Fast-acting Human Insulin Revenue, 2024-2029
5.2.3 By Application – Global Fast-acting Human Insulin Revenue Market Share, 2018-2029
5.3 By Application – Global Fast-acting Human Insulin Sales & Forecasts
5.3.1 By Application – Global Fast-acting Human Insulin Sales, 2018-2023
5.3.2 By Application – Global Fast-acting Human Insulin Sales, 2024-2029
5.3.3 By Application – Global Fast-acting Human Insulin Sales Market Share, 2018-2029
5.4 By Application – Global Fast-acting Human Insulin Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Fast-acting Human Insulin Market Size, 2022 & 2029
6.2 By Region – Global Fast-acting Human Insulin Revenue & Forecasts
6.2.1 By Region – Global Fast-acting Human Insulin Revenue, 2018-2023
6.2.2 By Region – Global Fast-acting Human Insulin Revenue, 2024-2029
6.2.3 By Region – Global Fast-acting Human Insulin Revenue Market Share, 2018-2029
6.3 By Region – Global Fast-acting Human Insulin Sales & Forecasts
6.3.1 By Region – Global Fast-acting Human Insulin Sales, 2018-2023
6.3.2 By Region – Global Fast-acting Human Insulin Sales, 2024-2029
6.3.3 By Region – Global Fast-acting Human Insulin Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Fast-acting Human Insulin Revenue, 2018-2029
6.4.2 By Country – North America Fast-acting Human Insulin Sales, 2018-2029
6.4.3 US Fast-acting Human Insulin Market Size, 2018-2029
6.4.4 Canada Fast-acting Human Insulin Market Size, 2018-2029
6.4.5 Mexico Fast-acting Human Insulin Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Fast-acting Human Insulin Revenue, 2018-2029
6.5.2 By Country – Europe Fast-acting Human Insulin Sales, 2018-2029
6.5.3 Germany Fast-acting Human Insulin Market Size, 2018-2029
6.5.4 France Fast-acting Human Insulin Market Size, 2018-2029
6.5.5 U.K. Fast-acting Human Insulin Market Size, 2018-2029
6.5.6 Italy Fast-acting Human Insulin Market Size, 2018-2029
6.5.7 Russia Fast-acting Human Insulin Market Size, 2018-2029
6.5.8 Nordic Countries Fast-acting Human Insulin Market Size, 2018-2029
6.5.9 Benelux Fast-acting Human Insulin Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Fast-acting Human Insulin Revenue, 2018-2029
6.6.2 By Region – Asia Fast-acting Human Insulin Sales, 2018-2029
6.6.3 China Fast-acting Human Insulin Market Size, 2018-2029
6.6.4 Japan Fast-acting Human Insulin Market Size, 2018-2029
6.6.5 South Korea Fast-acting Human Insulin Market Size, 2018-2029
6.6.6 Southeast Asia Fast-acting Human Insulin Market Size, 2018-2029
6.6.7 India Fast-acting Human Insulin Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Fast-acting Human Insulin Revenue, 2018-2029
6.7.2 By Country – South America Fast-acting Human Insulin Sales, 2018-2029
6.7.3 Brazil Fast-acting Human Insulin Market Size, 2018-2029
6.7.4 Argentina Fast-acting Human Insulin Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Fast-acting Human Insulin Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Fast-acting Human Insulin Sales, 2018-2029
6.8.3 Turkey Fast-acting Human Insulin Market Size, 2018-2029
6.8.4 Israel Fast-acting Human Insulin Market Size, 2018-2029
6.8.5 Saudi Arabia Fast-acting Human Insulin Market Size, 2018-2029
6.8.6 UAE Fast-acting Human Insulin Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi
7.1.1 Sanofi Company Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Fast-acting Human Insulin Major Product Offerings
7.1.4 Sanofi Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Key News & Latest Developments
7.2 Geropharm
7.2.1 Geropharm Company Summary
7.2.2 Geropharm Business Overview
7.2.3 Geropharm Fast-acting Human Insulin Major Product Offerings
7.2.4 Geropharm Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.2.5 Geropharm Key News & Latest Developments
7.3 Wockhardt
7.3.1 Wockhardt Company Summary
7.3.2 Wockhardt Business Overview
7.3.3 Wockhardt Fast-acting Human Insulin Major Product Offerings
7.3.4 Wockhardt Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.3.5 Wockhardt Key News & Latest Developments
7.4 Novo Nordisk
7.4.1 Novo Nordisk Company Summary
7.4.2 Novo Nordisk Business Overview
7.4.3 Novo Nordisk Fast-acting Human Insulin Major Product Offerings
7.4.4 Novo Nordisk Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.4.5 Novo Nordisk Key News & Latest Developments
7.5 Eli Lilly and Company
7.5.1 Eli Lilly and Company Company Summary
7.5.2 Eli Lilly and Company Business Overview
7.5.3 Eli Lilly and Company Fast-acting Human Insulin Major Product Offerings
7.5.4 Eli Lilly and Company Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.5.5 Eli Lilly and Company Key News & Latest Developments
7.6 Mannkind
7.6.1 Mannkind Company Summary
7.6.2 Mannkind Business Overview
7.6.3 Mannkind Fast-acting Human Insulin Major Product Offerings
7.6.4 Mannkind Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.6.5 Mannkind Key News & Latest Developments
7.7 Biocon
7.7.1 Biocon Company Summary
7.7.2 Biocon Business Overview
7.7.3 Biocon Fast-acting Human Insulin Major Product Offerings
7.7.4 Biocon Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.7.5 Biocon Key News & Latest Developments
7.8 Julphar
7.8.1 Julphar Company Summary
7.8.2 Julphar Business Overview
7.8.3 Julphar Fast-acting Human Insulin Major Product Offerings
7.8.4 Julphar Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.8.5 Julphar Key News & Latest Developments
7.9 ADOCIA
7.9.1 ADOCIA Company Summary
7.9.2 ADOCIA Business Overview
7.9.3 ADOCIA Fast-acting Human Insulin Major Product Offerings
7.9.4 ADOCIA Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.9.5 ADOCIA Key News & Latest Developments
7.10 Tonghua Dongbao Pharmaceutical
7.10.1 Tonghua Dongbao Pharmaceutical Company Summary
7.10.2 Tonghua Dongbao Pharmaceutical Business Overview
7.10.3 Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Major Product Offerings
7.10.4 Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.10.5 Tonghua Dongbao Pharmaceutical Key News & Latest Developments
7.11 Gan & Lee Pharmaceuticals
7.11.1 Gan & Lee Pharmaceuticals Company Summary
7.11.2 Gan & Lee Pharmaceuticals Business Overview
7.11.3 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Major Product Offerings
7.11.4 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.11.5 Gan & Lee Pharmaceuticals Key News & Latest Developments
7.12 Zhejiang Hisun Pharmaceutical
7.12.1 Zhejiang Hisun Pharmaceutical Company Summary
7.12.2 Zhejiang Hisun Pharmaceutical Business Overview
7.12.3 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Major Product Offerings
7.12.4 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.12.5 Zhejiang Hisun Pharmaceutical Key News & Latest Developments
7.13 Wuhan Biology Chemical Pharmacy
7.13.1 Wuhan Biology Chemical Pharmacy Company Summary
7.13.2 Wuhan Biology Chemical Pharmacy Business Overview
7.13.3 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Major Product Offerings
7.13.4 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Sales and Revenue in Global (2018-2023)
7.13.5 Wuhan Biology Chemical Pharmacy Key News & Latest Developments
8 Global Fast-acting Human Insulin Production Capacity, Analysis
8.1 Global Fast-acting Human Insulin Production Capacity, 2018-2029
8.2 Fast-acting Human Insulin Production Capacity of Key Manufacturers in Global Market
8.3 Global Fast-acting Human Insulin Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Fast-acting Human Insulin Supply Chain Analysis
10.1 Fast-acting Human Insulin Industry Value Chain
10.2 Fast-acting Human Insulin Upstream Market
10.3 Fast-acting Human Insulin Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Fast-acting Human Insulin Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
